Stapokibart efficacy by asthma status in chronic rhinosinusitis with nasal polyps: a post hoc analysis of the CROWNS-2 trial

Résumé fourni par la source

Background: Asthma is a common comorbidity in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Stapokibart, a novel anti-interleukin-4 receptor alpha monoclonal antibody, demonstrated efficacy and safety in patients with CRSwNP in a phase 3 trial (NCT05436275). Objective: To evaluate stapokibart’s efficacy and safety in patients with CRSwNP with/without comorbid asthma. Methods: Patients were randomized (1:1) to subcutaneous stapokibart 300 mg or placebo Q2W for 24 weeks. Post-hoc subgroup analyses (with/without comorbid asthma) assessed changes from baseline in nasal polyp score (NPS), nasal congestion score (NCS), Lund–Mackay computed tomography (CT) score, total symptom score (TSS), loss-of-smell score, 22-item Sino-nasal Outcome Test (SNOT-22) score, University of Pennsylvania Smell Identification Test (UPSIT) score, along with NPS and NCS response rates. Results: Of 179 patients, 89 (49.7%) had comorbid asthma. At week 24, stapokibart significantly improved NPS, NCS, Lund–Mackay CT score, UPSIT score, loss-of-smell score, TSS, and SNOT-22 score compared with placebo, irrespective of asthma status (all P < 0.01). Patients with comorbid asthma demonstrated greater improvements in TSS, olfactory function, and Lund–Mackay CT score at week 24 compared with those without comorbid asthma (all interaction P < 0.05). In the asthma subgroup, stapokibart increased the proportions of patients achieving ≥1- and ≥2-point reductions in NPS and ≥0.5- and ≥1-point reductions in NCS versus placebo (all P < 0.0001); among patients without asthma, similar trends were observed, although NCS response rates improvements did not reach statistical significance ( P = 0.086 and P = 0.052, respectively). The safety profile was similar across groups. Conclusion: Stapokibart improved NPS, NCS, Lund–Mackay CT score, UPSIT score, loss-of-smell score, TSS, and SNOT-22 score regardless of asthma status. Exploratory interaction analyses suggested potentially greater improvements in TSS, olfactory outcomes, and sinus opacification in patients with comorbid asthma.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.